why choose us

First received: October 27, 2023

Clinical Trial: Study of AZD9829 in CD123+ Hematological Malignancies

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Hematological Malignancies

Study Type: INTERVENTIONAL


Official Title: A Modular Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD9829 as Monotherapy or in Combination in Patients

Brief Summary: This is a modular, multicentre, open-label, Phase I/II, dose-setting study.AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.

Read more